Skip to content

Efficacy and safety of esketamine combined with propofol or ciprofol sedation for modified electroconvulsive therapy in patients with major depressive disorder: a Randomized, Double-Blind, Controlled Trial with Factorial Design

Efficacy and safety of esketamine combined with propofol or ciprofol sedation for modified electroconvulsive therapy in patients with major depressive disorder: a Randomized, Double-Blind, Controlled Trial with Factorial Design

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400083664
Enrollment
Unknown
Registered
2024-04-30
Start date
2024-05-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder

Interventions

EP:Esketamine + Propofol
EC:Esketamine + Ciprofol
NP:Normal saline + Propofol
NC:Normal saline + Ciprofol

Sponsors

Renmin hospital of Wuhan university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 65 Years

Inclusion criteria

Inclusion criteria: An independent investigator is responsible for recruiting subjects undergoing MECT. To be eligible, subjects have to be male or female, 14 to 65 years; meet The diagnostic and statistical manual of mental disorders-5 criteria for MDD; without psychotic features, confirmed by the Mini-International Neuropsychiatric Interview; American Society of Anesthesiologists (ASA) physical status class I or ?; schedule for MECT; sign informed consent for participation.

Exclusion criteria

Exclusion criteria: The key exclusion criteria include coexisted diagnosis of other psychotic disorder or nervous system diseases; be allergic or contraindicatic to study medications or any of their formulation ingredients; a recent history (past 6 months) of drug or alcohol abuse; pregnancy or lactation; refusal for participation.

Design outcomes

Primary

MeasureTime frame
The total scores of HADM-24;

Secondary

MeasureTime frame
The rate of response and remission;The incidence of adverse events;The details of anesthesia;The details of ECT;

Countries

China

Contacts

Public ContactQingtao Meng

Renmin hospital of Wuhan university

mengqingtao2018@126.com+86 139 9556 9560

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026